Compare Crispr Therapeutics AG (CRSP) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Corning Incorporated — how do they compare? Crispr Therapeutics AG trades at $53.89 (market cap $5.23B), while Corning Incorporated trades at $167.57 (market cap $137.12B). The key difference: Corning Incorporated is far larger — about 26.2× Crispr Therapeutics AG's market cap, and Corning Incorporated pays a 0.7% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | GLW | |
|---|---|---|
Market Cap | $5.23B | $137.12B |
Sector | Health | Technology |
52-Week High | $76.78 | $255.79 |
52-Week Low | $44.34 | $64.52 |
Enterprise Value | $3.65B | $144.00B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Corning (GLW) trades at $157.74, down 4.8% in the last session amid broader market volatility. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and projected 2026 revenue growth to $17B. Technical indicators are mixed with a neutral overall signal while valuation metrics remain elevated with a P/E of 73.36. Recent analyst upgrades highlight AI infrastructure and optical communications growth potential.
GLW presents a compelling growth story driven by AI data center demand and optical communications expansion, though premium valuation requires flawless execution. Key risks include competitive pressures in photonics and sensitivity to technology spending cycles. With 57% analyst buy ratings and a $193.33 consensus target offering 23% upside, the stock warrants consideration for growth-oriented investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
